Arrowhead Pharmaceuticals’ REDEMPLO (plozasiran), a small interfering RNA therapy, was recently approved by Australia’s Therapeutic Goods Administration as the first and only medicine to reduce ...

Despite experiencing significant reductions in triglycerides, patients with triglycerides over 150 mg/dL and a high risk of atherosclerosis did not experience any significant change in the amount of ...

The higher a person’s triglyceride levels, the more likely they are to experience acute pancreatitis. Very high triglycerides occur when triglyceride levels reach 500 milligrams per deciliter (mg/dl), ...

What Is Redemplo, and Why Does It Matter? Redemplo (plozasiran) is a type of medicine called a small interfering RNA (siRNA) therapy approved to help lower extremely high triglyceride levels in adults ...

—Analysis of CD4+ and CD8+ T cells from patients with varying lipid levels suggests new role for hypertriglyceridemia in CVD risk. Moderate—but not severe—hypertriglyceridemia has been shown to be ...

Plozasiran is the first FDA-approved drug for familial chylomicronemia syndrome, reducing triglycerides as an adjunct to diet. The phase 3 PALISADE trial showed significant triglyceride reduction with ...

Altering a single gene may help people lower dangerously high levels of cholesterol and other fats in the blood, according to new research presented Saturday at the annual meeting of the American ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. People with severe hypertriglyceridemia, defined as ...

Olezarsen decreased levels of triglycerides compared with placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, according to a late-breaking trial presented in a Hot ...

Both doses of olezarsen significantly reduced triglyceride levels at 6 months compared with placebo (placebo-adjusted reduction, 50mg: 58%; 80mg: 61%; P .0001). Topline data were announced from a ...

Ionis Pharmaceuticals IONS recently announced positive top-line results from the phase III ESSENCE study evaluating its wholly owned drug Tryngolza in people with moderate hypertriglyceridemia who ...